Table 4.
Disease control for patients who received thoracic proton SBRT
| Outcome | Overall (N=27) |
Early-Stage NSCLC (N=13) |
Locally Recurrent NSCLC (N=3) |
Metastatic Disease (N=11) |
|---|---|---|---|---|
| RECIST 1.1 response at first scan † | ||||
| Mean % change (SD) | −23.3 (22.1) | −28.0 (13.9) | −18.8 (14.6) | −19.0 (30.4) |
| Partial response | 9 (33.3%) | 5 (38.5%) | 1 (33.3%) | 3 (27.3%) |
| Stable disease | 17 (63.0%) | 8 (61.5%) | 2 (66.7%) | 7 (63.6%) |
| Progressive disease | 1 (3.7%) | 0 (0%) | 0 (0%) | 1 (9.1%) |
| Overall survival, months | ||||
| Median (IQR) months | 14 (10−23) | 15 (11−19) | 29 (29−30) | 11 (6−15) |
| 3-year actuarial outcomes (%) | ||||
| Local control | 77% | 89% | 100% | 43% |
| Regional control | 85% | 89% | 67% | 86% |
| DMFS | 52% | 79% | 100% | 0% |
†Irradiated tumor
Abbreviations: DMFS, distant metastasis-free survival; PFS, progression-free survival